Post COVID-19 condition in hospitalized survivors after one year of infection during the Alpha- and Delta-variant dominant waves in Japan: COVID-19 Recovery Study II.

Publication date: Feb 08, 2025

BackgroundEvidence of post-COVID-19 condition (PCC) in the Alpha- and Delta-variant dominant waves is limited. MethodsIn a nationwide multicentre cohort study in collaboration with 20 hospitals, we collected data using self-administered questionnaires and electronic medical records of participants aged 20 or more diagnosed with COVID-19, hospitalized between Apr 1 2021 and Sept 30 2021, and discharged alive. Descriptive statistics were analyzed for PCC and mental health (HADS anxiety and depression scores), comparing Alpa and Delta-dominant waves. ResultsWe analyzed 1,040 patients (median age, 57 [IQR 49-66] years; men, 66. 2%). Of the respondents, 45. 4% had at least one PCC symptom one year after infection. The common symptoms included dyspnea (20. 7%), fatigue/malaise (17. 6%), muscle weakness (15. 4%), decrease in concentration (13. 4%), and sleep disorder (13. 3%), followed by brain fog (8. 4%). Among patients with PCC, 14. 0% had anxiety (HADS-Anxiety ≥11), and 18. 6% had depression (HADS-Depression ≥11), with four times higher proportions than those without PCC; only small variations by age, sex, and waves were observed. Associated factors for PCC were age 40 years or over, women, severity of COVID-19 during hospitalization, ex-smokers who quit smoking before COVID-19 infection and being infected during the Delta-variant dominant wave. ConclusionThe study described the prevalence of PCC, associated factors, and mental health of COVID-19 survivors hospitalized during the Alpha and Delta-variant dominant waves in Japan. Further follow-up will be conducted to examine the longer-term impact of COVID-19 on PCC, complications, daily life, and socioeconomic status.

Concepts Keywords
Hospitalization COVID-19
Pcc mental health
Socioeconomic post-COVID-19 condition
the Alpha variant
the Delta variant

Semantics

Type Source Name
disease MESH COVID-19
disease MESH infection
drug DRUGBANK Factor IX Complex (Human)
disease MESH anxiety
disease MESH depression
disease IDO symptom
disease MESH dyspnea
disease MESH sleep disorder
disease MESH brain fog
disease MESH complications
disease MESH Long Covid

Original Article

(Visited 2 times, 1 visits today)